Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Caudal type homeobox 2 (CDX2) is a homeobox-containing transcription factor that plays a pivotal role in intestinal development and homeostasis by governing the identity and differentiation of the intestinal epithelium[1][2][6]. It acts as a major regulator in both stem/progenitor and differentiated intestinal cells, primarily through binding DNA and modulating gene expression. CDX2’s activities extend beyond traditional gene transcription, also impacting cellular pathways such as Wnt and NF-κB, DNA repair, and RNA splicing[1]. Loss or aberrant expression of CDX2 is closely linked to colorectal cancer and serves as a diagnostic and prognostic biomarker in gastrointestinal oncology. Additionally, CDX2 can be ectopically expressed in non-intestinal tissues, where it is implicated in disease processes such as metaplasias and certain leukemias[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caudal type homeobox 2 (CDX2).